Access to relevant patient populations continue to be an allusive keystone for the clinical trials industry. Countless potentially life-changing new medications are delayed due to slow study enrollment resulting in Pharma spending millions on delays, and worse, missing revenue due to the loss of patent protection (which can be in the billions).
At MedVector, we believe patients want to hear about clinical trials from their trusted provider (HCP), not a Facebook ad… With this in mind, we have developed the first “HCP Recruitment” company to encourage local providers to have conversations with their patients about local clinical trial opportunities.
The secret to our success is protecting the doctor/patient relationship by hosting certain study visits from local provider’s practices and compensating them for the time spent in their office. All MedVector visits utilize telemedicine, enabling Investigator Teams to DIRECT, SUPERVISE, and ENTER PROTOCOL DATA in real-time during study visits. The result exponentially increases access to diverse patient populations, accelerates enrollment, and minimizes dropouts.